Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 11 JUNE 2024

Magnifying MedsCheck Misuse: Pharmacists Take Note

Rosen Sunshine LLP
Explore more from Rosen Sunshine LLP

Recent news stories have highlighted concerns that pharmacists are misusing the MedsCheck program which reimburses pharmacies for conducting medication reviews.

CanadaFood, Drugs, Healthcare, Life Sciences
Elyse Sunshine
Elyse Sunshine
Melina Fazzari
Melina Fazzari
Author LinkedIn connections

Recent news stories have highlighted concerns that pharmacists are misusing the MedsCheck program which reimburses pharmacies for conducting medication reviews . On February 28, 2024 a CBC news report was published where pharmacists expressed feeling pressured by management to conduct unnecessary reviews with low-risk patients and to bill the government.

The Ontario MedsCheck Program

MedsCheck is a government program that reimburses an Ontario pharmacy when a pharmacist meets with a patient to review their medications. Under MedsCheck, the pharmacist can schedule a 20- to 30-minute annual review with patients who are:

  • taking at least three prescription medications for a chronic condition,

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

More Than Skin Deep: Ontario Considers A Makeover Of Cosmetic Injection Rules

A regulatory shift now under consideration in Ontario could reshape how the province’s medical aesthetic clinics operate. The proposal, which would change how nurses are authorized to administer medical aesthetic services, invites a broader look at how Ontario currently regulates cosmetic injections and how the proposed changes would align the province more closely with the regulatory frameworks already in place elsewhere in Canada. While these procedures are often marketed as routine “spa” services, they remain medical acts that involve prescription products and carry clinical risks.
CanadaFood, Drugs, Healthcare, Life Sciences
Fasken
Fasken
Article

Life Sciences-Health Canada Takes Action Against Unauthorized Peptide Sales

On July 29, 2026, Health Canada announced that it had obtained a permanent injunction against a Québec-based company in connection with the sale of unauthorized injectable peptides in Canada. The announcement reflects Health Canada’s continued focus on peptide products and serves as a reminder that injectable peptides intended for human use are regulated as prescription drugs and are subject to Canada's drug regulatory framework.
CanadaFood, Drugs, Healthcare, Life Sciences
Fasken
Fasken
Article

Health Canada Updates Policies On Foreign Regulatory Actions, Summary Reporting, Compliance & Enforcement And Requests For New Data

Health Canada issued revised guidance on notifying Health Canada of foreign actions, effective October 1, 2026. The revised guidance clarifies the requirements to notify Health Canada of certain foreign regulatory actions specified in subsection C.01.050(2) of the Food and Drug Regulations in the specified foreign jurisdictions, which involve a serious risk of injury to human health and are relevant to the safety of the drug.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar
Article

Health Canada Launches Clinical Trial Search Portal And Registration And Results Disclosure Guidance

While not currently legally binding, the guidance sets clear expectations for clinical trial registration and results disclosure and signals Health Canada’s broader push for transparency in clinical research. Health Canada describes this policy-first approach as a way to allow sponsors to adapt before potential regulatory requirements are introduced. For sponsors conducting clinical trials in Canada, the announcement therefore represents more than the launch of a new public-facing tool, it provides an indication of the direction of Canada’s evolving clinical trial framework.
CanadaFood, Drugs, Healthcare, Life Sciences
Fasken
Fasken